Heart drug study halted early: limited data on right heart changes
NCT ID NCT04954742
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether the drug riociguat could improve right heart size and function in people with two types of pulmonary hypertension (PAH and CTEPH). It planned to enroll 30 adults, but was terminated early, so results are limited. The goal was to use echocardiograms to measure changes in the heart's right chambers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for Pulmonary Hypertension at the Thoraxklinik Heidelberg, Heidelberg University Hospital
Heidelberg, 69126, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A tiny sensor inside the lung could reveal hidden pressure problems after Life-Saving surgery
- Prepping the body before heart surgery: could exercise shorten hospital stays?
- Registry aims to uncover long-term outlook for rare blood-clot lung disease
- Could pedaling backward help heart and lung patients get stronger?
- Recovery after lung surgery: new study tracks Patients' strength and breathing
- Kidney risk after lung surgery: new clues from 150 patients